1. Introduction {#sec1}
===============

Autoimmune thyroid diseases (AITDs) are a type of T cell-mediated organ-specific autoimmune diseases, the prevalence of which is more than 5% and result from loss of immune tolerance or autoimmune attack to the thyroid itself; they mainly include Graves\' disease (GD) and Hashimoto\'s thyroiditis (HT) \[[@B1]--[@B3]\]. The main cause of clinical hyperthyroidism and hypothyroidism is GD and HT, respectively \[[@B1], [@B4]\]. Hyperthyroidism in GD is attributed to thyroid-stimulating autoantibodies to the TSH receptor, whereas hypothyroidism in HT is related to autoantibodies against thyroid peroxidase and thyroglobulin \[[@B5]\]. The pathogenesis of AITD is thought to be the interaction between susceptibility genes and environmental factors. Recent studies have identified a number of susceptibility loci for AITD, including *CD40* \[[@B6]\], interleukin 10 \[[@B7]\], miR-499a and miR-125a \[[@B8]\], cytotoxic T lymphocyte-associated protein 4 (*CTLA4*), and human leukocyte antigen (*HLA*) \[[@B9]\].

Interferon (IFN) regulatory factors (IRFs), namely, transcriptional regulators of type I IFNs and IFN-inducible genes, play a pivotal role in innate and adaptive immune responses \[[@B10]\]. IRF7, a member of the IRF family, is required for type I IFN production and can regulate type I IFN-dependent immune responses \[[@B11]\]. Recent studies have indicated that polymorphisms in *IRF7* gene are associated with immunity-mediated diseases, systemic lupus erythematosus (SLE) \[[@B12], [@B13]\] and systemic sclerosis \[[@B14]\]. These studies have contributed to understanding the relationship between the *IRF7* gene mutations and the risk of autoimmune disease, but it is unknown whether *IRF7* gene variations increase or decrease the susceptibility to AITDs.

The purpose of this case-control study was to explore the association of *IRF7* gene polymorphisms with AITDs in a Chinese Han population. Furthermore, we analyzed the correlation between genotypes of *IRF7* gene and AITD clinical phenotypes.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

A total of 1659 subjects consisting of 889 AITD patients (220 males and 669 females; mean age of 36.29 ± 14.31 years) and 770 controls (216 males and 544 females; mean age of 39.04 ± 8.79 years) were enrolled in this study. The AITD patients were clinically subdivided into 592 GD (179 males and 413 females; mean age of 36.95 ± 14.70 years) and 297 HT (41 males and 256 females; mean age of 34.96 ± 13.42 years). All the AITD patients were recruited from the Outpatient Department of Endocrinology of Jinshan Hospital of Fudan University. GD was diagnosed based on hyperthyroidism and the positive circulating thyroid stimulating hormone receptor antibody (TRAb). HT was defined by high level of positive antibody against thyroid peroxidase (TPOAb) or thyroglobulin (TGAb), with or without hypothyroidism and the presence of an enlarged thyroid.

The controls were healthy individuals recruited from the Check-Up Center of the same hospital. Those controls with any autoimmune disease or family history of thyroid diseases were excluded. All subjects were of Chinese Han ethnicity. The written informed consent was obtained from all the participants. This study was approved by the ethics committee of the hospital.

The clinical phenotypes of AITD patients included the presence or absence of family history within three generations, with or without ophthalmopathy, the onset age (≤18 years vs. ≥19 years), euthyroid status, or hypothyroidism in HT patients.

2.2. Genomic DNA Extraction {#sec2.2}
---------------------------

We obtained 2 mL of peripheral venous blood from all the subjects by venipuncture and then extracted genomic DNA using RelaxGene Blood DNA System (Tiangen Biotech, Beijing, China) according to the manufacturer\'s guidelines. The concentration and purity of DNA from each sample were detected using NanoDrop 2000 Spectrophotometer (Thermo Scientific Company, Waltham, USA).

2.3. SNP Selection and Genotyping {#sec2.3}
---------------------------------

We selected three loci of rs1061501, rs1131665, and rs1061502 in the *IRF7* region because of their strong association with other autoimmune diseases like SLE and systemic sclerosis \[[@B13], [@B14]\]. Furthermore, marker-tagging SNPs had to meet the criteria of minor allele frequency (MAF) \> 0.01, Hardy--Weinberg equilibrium (HWE) with *P* \> 0.01, and logarithm of odds (LOD) \> 3.0.

The genotyping of three SNPs of *IRF7* was performed using ligase detection reactions (LDR) platform \[[@B15]--[@B17]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

All statistical analyses were performed using SPSS software (version 17.0).

The clinical data of the subjects are presented as M ± SD. The differences in genotype and allele frequency distributions were analyzed by *χ*^2^ test or Fisher\'s exact test. HWE test, linkage disequilibrium (LD), and haplotype frequency were performed using HaploView 4.2. Odds ratio (OR) and 95% confidence interval (CI) were calculated for the association of genotype or allele frequencies with AITDs.

3. Results {#sec3}
==========

3.1. Clinical Data Analysis {#sec3.1}
---------------------------

Clinical data of all the subjects were summarized in [Table 1](#tab1){ref-type="table"}. Our study investigated 889 AITD patients, consisting of 592 GD patients (30.24% males and 69.76% females; mean age of 36.95 ± 14.70 years) and 297 HT ones (13.80% males and 86.20% females; mean age of 34.96 ± 13.42 years). Among the AITDs patients, there were 181 (20.36%) cases with a family history, 111 (12.49%) cases with ophthalmopathy, and 161 (13.72%) cases who were teenager patients with an onset age of ≤18 years old. Among the GD patients, 120 individuals had a family history, 106 had ophthalmopathy, and 83 with an onset age of ≤18 years old (20.27%, 17.91%, and 14.02%, respectively). While in the HT patients, 61 individuals had a family history, 5 had ophthalmopathy and 39 with an onset age of ≤18 years old (20.54%, 1.68%, and 13.13%, respectively).

3.2. Allele and Genotypic Results {#sec3.2}
---------------------------------

The genotype distributions of these three SNPs (rs1061501/rs1131665/rs1061502) were in Hardy--Weinberg equilibrium (*P* \> 0.05) in both AITD patients and controls (data not shown). Differences in genotypic and allelic frequencies of these three SNPs between AITD patients and controls were compared ([Table 2](#tab2){ref-type="table"}). For rs1131665, the AG genotype frequency and the minor allele G frequency in AITD patients were both significantly higher than those of the controls (AG genotype: 4.5% vs. 2.3%, *P* = 0.017, OR = 1.968, 95% CI = 1.119-3.463; allele G: 2.2% vs. 1.2%, *P* = 0.018, OR = 1.946, 95% CI = 1.111-3.409). Similar trend was also found for rs1061502. However, no significant differences in both allele and genotype frequencies of rs1061501 were found between AITD patients and the controls.

As shown in [Table 3](#tab3){ref-type="table"}, subgroup analysis showed that the AG genotype frequency of rs1131665 and rs1061502 in GD patients was significantly higher than that of the controls (*P* = 0.015, OR = 2.074, 95% CI = 1.136-3.787; *P* = 0.034, OR = 1.919, 95% CI = 1.042-3.535, respectively). The minor allele G frequency of rs1131665 and rs1061502 in GD patients was also significantly higher than that of the controls (*P* = 0.016, OR = 2.048, 95% CI = 1.127-3.721; *P* = 0.035, OR = 1.898, 95% CI = 1.036-3.479, respectively). No significant difference in the three SNPs, however, was found between HT patients and the controls.

3.3. Genotype and Clinical Phenotype Correlations {#sec3.3}
-------------------------------------------------

We also analyzed the association of genotypes with clinical phenotypes, including age of onset (≤18 years old or ≥19 years old) in AITD patients, with or without ophthalmopathy in GD patients, hypothyroidism, or euthyroidism in HT patients.

[Table 4](#tab4){ref-type="table"} displayed that the allele G frequency of rs1061501 in GD patients with ophthalmopathy was significantly higher than that of GD patients without ophthalmopathy (*P* = 0.035, OR = 1.396, 95% CI = 1.023-1.906). As shown in Tables [5](#tab5){ref-type="table"} and [6](#tab6){ref-type="table"}, we did not find any difference in specific genotype frequency or allele frequency in AITD patients with different age of disease onset, also in HT patients accompanied with hypothyroidism or not (all *P* \> 0.05).

4. Discussion {#sec4}
=============

To our knowledge, the present study was the first to investigate the association of *IRF7* polymorphisms with the susceptibility to AITDs. Our results showed that AG genotype and the minor G allele of rs1131665 and rs1061502 significantly increased the risk of AITDs and GD. More importantly, the minor G allele of rs1061501 was associated with ophthalmopathy in GD patients.

In concordance with our study, Fu et al. have shown that the polymorphisms of rs1131665 in *IRF7* conferred susceptibility to the development of SLE in multiple ethnic groups, including Asians, Chinese, and European Americans. Moreover, their meta-analysis provided direct genetic evidence that *IRF7* is a risk gene for human SLE \[[@B18]\]. Another study involving 2316 SSc patients and 2347 healthy controls demonstrated a significant association of rs1131665 polymorphisms with the presence of anticentromere autoantibodies (ACA) in SSc patients \[[@B14]\]. The TT genotype and T allele of rs1061501 in *IRF7* were also found to be associated with an increased risk of developing SLE among Taiwanese patients, but no significant difference in rs1061502 SNP was found between SLE patients and controls \[[@B13]\]. One possible explanation is that their small sample size (92 SLE patients and 92 healthy controls) caused lower statistical power.

*IRF7* is localized on human chromosome 11p15.5 and interacts with the MyD88 adaptor protein downstream of Toll-like receptor (TLR) signaling \[[@B19]\]. *IRF7* can induce a large amount of type I IFN after being activated by TLR7 and TLR9 in plasmacytoid dendritic cells \[[@B20]\]. Interferon- (INF-) *α*, a type 1 INF, is widely used to treat chronic hepatitis C for its antiviral effects \[[@B21]\]. Furthermore, INF-*α* is also strongly linked with the occurrence of AITDs because it can evoke antibody-mediated immune responses \[[@B22], [@B23]\]. One study revealed that overt AITD occurred in about 5--10% of INF-*α*-treated patients \[[@B24]\]. A recent study has also found that 2% of patients developed hyperthyroidism in the HCV-positive patients during a 12-week course of INF-*α* antiviral therapy \[[@B25]\]. Therefore, studies have indicated that INF-*α* is one of the important immune factors that induce AITDs \[[@B26], [@B27]\].

Our results demonstrated that the AG genotype and minor allele G frequency of rs1131665 and rs1061502 in AITD patients and GD patients were both significantly higher than those of the controls, suggesting that minor allele G may be a risk factor for AITD and GD. However, neither the genotype nor allele of rs1131665, rs1061501, and rs1061502 was found to be associated with HT, indicating that the three SNPs were not involved in the pathogenesis of HT. These different results of the *IRF7* SNPs in GD and HT may be attributed to their different etiology. Intriguingly, the further genotyping-clinical phenotype correlation analysis showed that the allele G frequency of rs1061501 in GD patients with ophthalmopathy was significantly higher than that of GD patients without ophthalmopathy, conferring a significant degree of risk for ophthalmopathy in GD patients. Graves\' ophthalmopathy, a common extrathyroidal manifestation of GD, affects 25-50% of GD patients to various extent \[[@B28]\]. To date, its etiology remains unclear. To our knowledge, some genes have been related to Graves\' ophthalmopathy, such as thyroid-stimulating hormone receptor (TSHR), *CTLA-4*, *HLA-DRB-1*, and *TNF-α* \[[@B29]--[@B31]\]. Our results suggested the association of *IRF7* polymorphisms with Graves\' ophthalmopathy, thus adding *IRF7* to the list of predisposing genes of Graves\' ophthalmopathy. But according to our existing data, we cannot evaluate the association of IRF7 polymorphisms with the clinical activity, severity, and response to treatment of Graves\' ophthalmopathy, which needs to be further studied in the future.

Above all, our study was the first to investigate the association of *IRF7* gene polymorphisms with the susceptibility to AITD. Our study suggests that *IRF7* is a crucial risk factor for AITD and GD. Further researches aiming at identifying the function and mechanism of IRF7 in AITDs are needed to be conducted. Our results are needed to perform in other population. In addition, more attention should be paid to other loci of *IRF7* and the potential roles of *IRF7* in other autoimmune diseases.
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###### 

Clinical data of all subjects.

                      AITD            GD              HT              Control
  ------------------- --------------- --------------- --------------- --------------
  *N*                 889             592             297             770
  *Gender*            ---             ---             ---             ---
  Male                220 (24.75%)    179 (30.24%)    41 (13.80%)     266 (34.55%)
  Female              669 (75.25%)    413 (69.76%)    256 (86.20%)    504 (65.45%)
  Age (mean ± s.d.)   36.29 ± 14.31   36.95 ± 14.70   34.96 ± 13.42   39.04 ± 8.79
  *Family history*    ---             ---             ---             ---
  (+)                 181 (20.36%)    120 (20.27%)    61 (20.54%)     ---
  (-)                 708 (79.64%)    472 (79.73%)    236 (79.46%)    
  *Ophthalmopathy*                                                    
  (+)                 111 (12.49%)    106 (17.91%)    5 (1.68%)       ---
  (-)                 778 (87.51%)    486 (82.09%)    292 (98.32%)    ---
  *Onset of age*                                                      ---
  ≤18 years           122 (13.72%)    83 (14.02%)     39 (13.13%)     ---
  ≥19 years           767 (86.28%)    509 (85.98%)    258 (86.87%)    ---

AITD, autoimmune thyroid disease; GD, Graves\' disease; HT, Hashimoto\'s thyroiditis.

###### 

Allele and genotype frequencies of *IRF7* SNPs in controls and AITD patients.

  SNP         Genotype/allele   Control (%)   AITD (%)     *P*     OR            95% CI
  ----------- ----------------- ------------- ------------ ------- ------------- --------
  rs1061501   AA                344 (44.7)    423 (47.6)                         
  AG          357 (46.4)        376 (42.3)    0.237        ---     ---           
  GG          69 (9.0)          90 (10.1)                                        
  A           1045 (67.9)       1222 (68.7)   0.590        0.961   0.830-1.112   
  G           495 (32.1)        556 (31.3)                                       
                                                                                 
  rs1131665   AA                752 (97.7)    849 (95.5)                         
  AG          18 (2.3)          40 (4.5)      0.017        1.968   1.119-3.463   
  GG          0 (0)             0 (0)                                            
  A           1522 (98.8)       1738 (97.8)   0.018        1.946   1.111-3.409   
  G           18 (1.2)          40 (2.2)                                         
                                                                                 
  rs1061502   AA                752 (97.7)    851 (95.7)                         
  AG          18 (2.3)          38 (4.3)      0.029        1.866   1.056-3.296   
  GG          0 (0)             0 (0)                                            
  A           1522 (98.8)       1740 (97.9)   0.031        1.847   1.050-3.249   
  G           18 (1.2)          38 (2.1)                                         

AITD, autoimmune thyroid disease; OR, odds ratio; 95% CI, 95% confidence intervals.

###### 

Allele and genotype frequencies of *IRF7* SNPs in GD, HT patients, and controls.

  SNP           Control (%)   GD (%)        *P*     OR (95% CI)           HT (%)       *P*     OR (95% CI)
  ------------- ------------- ------------- ------- --------------------- ------------ ------- ---------------------
  *rs1061501*                                                                                  
  AA            344 (44.7)    281 (47.5)    0.565   ---                   142 (47.8)   0.074   ---
  AG            357 (46.4)    258 (43.6)    ---     ---                   118 (39.7)   ---     ---
  GG            69 (9.0)      53 (9.0)      ---     ---                   37 (12.5)    ---     ---
  A             1045 (67.9)   820 (69.3)    0.436   0.937 (0.796-1.103)   402 (67.7)   0.936   1.008 (0.823-1.235)
  G             495 (32.1)    364 (30.7)                                  192 (32.3)           
  *rs1131665*                                                                                  
  AA            752 (97.7)    564 (95.3)    0.015   2.074 (1.136-3.787)   285 (96.0)   0.132   1.759 (0.837-3.698)
  AG            18 (2.3)      28 (4.7)                                    12 (4.0)             ---
  GG            0 (0)         0 (0)                                       0 (0)                
  A             1522 (98.8)   1156 (97.6)   0.016   2.048 (1.127-3.721)   582 (98.0)   0.134   1.743 (0.835-3.642)
  G             18 (1.2)      28 (2.4)                                    12 (2.0)             
  *rs1061502*                                                                                  
  AA            752 (97.7)    566 (95.6)    0.034   1.919 (1.042-3.535)   285 (96.0)   0.132   1.759 (0.837-3.698)
  AG            18 (2.3)      26 (4.4)                                    12 (4.0)             ---
  GG            0 (0)         0 (0)                                       0 (0)                
  A             1522 (98.8)   1158 (97.8)   0.035   1.898 (1.036-3.479)   582 (98.0)   0.134   1.743 (0.835-3.642)
  G             18 (1.2)      26 (2.2)                                    12 (2.0)             

GD, Graves\' disease; HT, Hashimoto\'s thyroiditis; OR, odds ratio; 95% CI, 95% confidence intervals.

###### 

*IRF7* genotype and allele distribution in ophthalmopathy or nonophthalmopathy GD patients.

  SNP         GD            *P*           OR (95% CI)   
  ----------- ------------- ------------- ------------- ----------------------
  rs1061501   ---           ---           ---           ---
  AA          41 (38.7%)    240 (49.4%)   ---           ---
  AG          52 (49.1)     206 (42.4%)   0.102         ---
  GG          13 (12.3)     40 (8.2%)     ---           ---
  A           134 (63.2%)   686 (70.6%)   0.035         1.396 (1.023-1.906)
  G           78 (32.8%)    286 (29.4%)   ---           ---
  rs1131665   ---           ---           ---           ---
  AA          104 (99.1%)   460 (97.3%)   ---           ---
  AG          2 (0.9%)      26 (2.7%)     0.128         2.939 (0.687-12.579)
  GG          0 (0%)        0 (0%)        ---           ---
  A           210 (98.2%)   946 (97.6%)   0.133         2.886 (0.680-12.253)
  G           2 (1.8%)      26 (2.4%)     ---           ---
  rs1061502   ---           ---                         
  AA          104 (99.1%)   462 (95.1%)   ---           ---
  AG          2 (0.9%)      24 (4.9%)     0.259         2.701 (0.629-11.610)
  GG          0 (0%)        0 (0%)        ---           ---
  A           210 (98.2%)   948 (97.5%)   0.265         2.658 (0.623-11.335)
  G           2 (1.8%)      24 (2.5%)     ---           ---

GD, Graves\' disease; OR, odds ratio; 95% CI, 95% confidence intervals.

###### 

Allele and genotype distribution of *IRF7* in AITDs patients with or without early onset age.

  SNP         Onset age of AITDs patients   *P*            OR (95% CI)   
  ----------- ----------------------------- -------------- ------------- ---------------------
  rs1061501   ---                           ---            ---           ---
  AA          65 (53.3%)                    358 (46.7%)    ---           ---
  AG          48 (39.3)                     328 (42.8%)    0.315         ---
  GG          9 (7.4)                       81 (10.6%)     ---           ---
  A           178 (73%)                     1044 (68.1%)   0.126         1.266 (0.936-1.712)
  G           66 (27%)                      490 (31.9%)    ---           ---
  rs1131665   ---                           ---            ---           ---
  AA          115 (94.3%)                   734 (95.7%)    ---           ---
  AG          7 (5.7%)                      33 (4.3%)      0.477         0.739 (0.319-1.709)
  GG          0 (0%)                        0 (0%)         ---           ---
  A           237 (97.1%)                   1501 (97.8%)   0.483         0.744 (0.326-1.702)
  G           7 (2.9%)                      33 (2.2%)      ---           ---
  rs1061502   ---                           ---                          
  AA          115 (94.3%)                   736 (96%)      ---           ---
  AG          7 (5.7%)                      31 (4%)        0.390         0.692 (0.298-1.608)
  GG          0 (0%)                        0 (0%)         ---           ---
  A           237 (97.1%)                   1503 (98%)     0.395         0.698 (0.304-1.604)
  G           7 (2.9%)                      31 (2%)        ---           ---

AITD, autoimmune thyroid disease; OR, odds ratio; 95% CI, 95% confidence intervals.

###### 

*IRF7* genotype and allele distribution in clinical subphenotype of HT patients.

  SNP         HT            *P*           OR (95% CI)   
  ----------- ------------- ------------- ------------- ---------------------
  rs1061501   ---           ---           ---           ---
  AA          94 (48.5%)    48 (46.6%)    ---           ---
  AG          73 (37.6)     45 (43.7%)    0.443         ---
  GG          27 (13.9)     10 (9.7%)     ---           ---
  A           261 (67.3%)   141 (68.4%)   0.770         0.947 (0.659-1.361)
  G           127 (32.7%)   65 (31.6%)    ---           ---
  rs1131665   ---           ---           ---           ---
  AA          187 (96.4%)   98 (95.1%)    ---           ---
  AG          7 (3.6%)      5 (4.9%)      0.834         1.363 (0.422-4.406)
  GG          0 (0%)        0 (0%)        ---           ---
  A           381 (98.2%)   201 (97.6%)   0.836         1.354 (0.424-4.320)
  G           7 (1.8%)      5 (2.4%)      ---           ---
  rs1061502   ---           ---                         
  AA          187 (96.4%)   98 (95.1%)    ---           ---
  AG          7 (3.6%)      5 (4.9%)      0.834         1.363 (0.422-4.406)
  GG          0 (0%)        0 (0%)        ---           ---
  A           381 (98.2%)   201 (97.6%)   0.836         1.354 (0.424-4.320)
  G           7 (1.8%)      5 (2.4%)      ---           ---

HT, Hashimoto\'s thyroiditis; OR, odds ratio; 95% CI, 95% confidence intervals.
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